2023 Targeted Therapies of Lung Cancer Meeting (Poster)-P1.23. Mutations in the RNA Binding Motif Protein 10 (RMB10) in NSCLC Are Highly Associated with Multiple Actionable Driver Mutatio

P1.23. Mutations in the RNA Binding Motif Protein 10 (RMB10) in NSCLC Are Highly Associated with Multiple Actionable Driver Mutatio

Back to course

Pdf Summary

RNA splicing defects have been identified as molecular characteristics of cancer, and mutations in genes encoding RNA splicing factors are frequently found in non-small cell lung cancer (NSCLC). The RNA binding motif protein 10 (RBM10) is one such factor, and its mutations have been associated with NSCLC progression. In this study, the researchers analyzed RBM10 mutations in NSCLC cases from the AACR cbioportal GENIE cohort. They identified 1,182 unique cases with RBM10 mutations, accounting for 7.0% of NSCLC cases. These RBM10 mutations were strongly associated with other actionable driver mutations in NSCLC, including KRAS G12C and EGFR L858R. They also found that a significant proportion of RBM10 mutations co-occurred with mutations in genes such as STK11, KEAP1, and NFE2L2. The study suggests that targeting RNA splicing, either alone or in combination with specific on-target inhibition, may improve the efficacy of current therapy for NSCLC. Overall, these findings highlight the importance of understanding the role of RNA splicing defects in cancer and the potential for developing targeted therapies in NSCLC based on these molecular characteristics.

Asset Subtitle

Danielle Brazel, University of California Irvine, United States

Meta Tag

Speaker Danielle Brazel, University of California Irvine, United States

Topic Poster Listing

Keywords

RNA splicing defects

cancer

mutations

genes

non-small cell lung cancer

NSCLC

RBM10

driver mutations

targeting RNA splicing

targeted therapies